drugset / Trial / NCT06567366
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy and safety of CAR T-cell therapy in combination with glofitamab for the treatment of relapsed/refractory large B-cell lymphoma with high-risk prognostic factors.
Timeline
- Start
- 2024-09
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR T-cell therapy | Cell therapy | — | Other |
| Subject | Glofitamab | Monoclonal antibody | 2.5 mg | Intravenous |
| Subject | Glofitamab | Monoclonal antibody | 10 mg | Intravenous |
| Subject | Glofitamab | Monoclonal antibody | 30 mg | Intravenous |
| Background | Obinutuzumab | Monoclonal antibody | 1 g | Intravenous |